David Gort self-funded his Harvoni treatment because it was unclear when the NHS funded treatment would be provided. Read more about David Gort self-funded his Harvoni treatment because it was unclear when the NHS funded treatment would be provided.
A witness borrowed £60,000 to access Harvoni treatment privately. He explained "I couldn't bear the pain of not knowing how long I would have to wait. It felt like I was playing Russian roulette with my life." Ultimately the treatment was funded by the NHS. Read more about A witness borrowed £60,000 to access Harvoni treatment privately. He explained "I couldn't bear the pain of not knowing how long I would have to wait. It felt like I was playing Russian roulette with my life." Ultimately the treatment was funded by the NHS.
Robert James, a campaigner involved in the field of patient involvement and treatment activism, stated that the rationing of DAAs by NHS England delayed the availability of effective Hepatitis C treatment to many people with haemophilia in England. Read more about Robert James, a campaigner involved in the field of patient involvement and treatment activism, stated that the rationing of DAAs by NHS England delayed the availability of effective Hepatitis C treatment to many people with haemophilia in England.
Samantha May, Helpline Information and Support Service Manager for the Hepatitis C Trust, stated that when new treatments first became available, "we frequently heard from our callers that their consultants told them they were "lucky" to receive this new treatment and they should be "grateful" due to the initial high cost." Read more about Samantha May, Helpline Information and Support Service Manager for the Hepatitis C Trust, stated that when new treatments first became available, "we frequently heard from our callers that their consultants told them they were "lucky" to receive this new treatment and they should be "grateful" due to the initial high cost."
Professor Graham Foster responded to concerns about lack of consistency in monitoring of Hepatitis C in England. He favoured an individualised approach to management of Hepatitis C in consultation with the patient. Read more about Professor Graham Foster responded to concerns about lack of consistency in monitoring of Hepatitis C in England. He favoured an individualised approach to management of Hepatitis C in consultation with the patient.
Professor Graham Foster was asked about the services, including testing and treatment, offered to those identified via the Hepatitis C elimination programme. He explained that treatment services are dependent on the local area, however, broadly, patients are offered a liver fibrosis assessment and subsequently a multi-disciplinary meeting is held to discuss treatment needs. Read more about Professor Graham Foster was asked about the services, including testing and treatment, offered to those identified via the Hepatitis C elimination programme. He explained that treatment services are dependent on the local area, however, broadly, patients are offered a liver fibrosis assessment and subsequently a multi-disciplinary meeting is held to discuss treatment needs.
Professor Graham Foster explained the phases of NHS England's Hepatitis C elimination programme. Read more about Professor Graham Foster explained the phases of NHS England's Hepatitis C elimination programme.
Funding for DAAs was provided through operational delivery networks across England. Each one was provided with a proportion of the budget for Hepatitis C treatment based on the estimated treatment figures for the area covered and the local prevalence of Hepatitis C. Read more about Funding for DAAs was provided through operational delivery networks across England. Each one was provided with a proportion of the budget for Hepatitis C treatment based on the estimated treatment figures for the area covered and the local prevalence of Hepatitis C.
Professor John Dillon, clinical lead for Hepatitis C in NHS Tayside, described the approach to treatment of Hepatitis C in Scotland. Read more about Professor John Dillon, clinical lead for Hepatitis C in NHS Tayside, described the approach to treatment of Hepatitis C in Scotland.
Scotland introduced a policy of prioritising antiviral therapy for those with moderate to severe liver disease. The policy of prioritisation ended in 2018. Read more about Scotland introduced a policy of prioritising antiviral therapy for those with moderate to severe liver disease. The policy of prioritisation ended in 2018.